Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155)
Semin Oncol
.
2019 Feb;46(1):104-105.
doi: 10.1053/j.seminoncol.2018.12.005.
Epub 2019 Jan 2.
Authors
Mario Caccese
1
,
Fililppo Ceccato
2
,
Matteo Fassan
3
,
Ambrogio Fassina
3
,
Marta Padovan
4
,
Isabella Mammi
5
,
Maurizio Iacobone
6
,
Carla Scaroni
2
,
Vittorina Zagonel
4
,
Giuseppe Lombardi
4
Affiliations
1
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Electronic address: mario.caccese@iov.veneto.it.
2
Endocrinology Unit, Department of Medicine DIMED, University-Hospital of Padova, Padova, Italy.
3
Surgical Pathology Unit, Department of Medicine (DIMED), University Hospital of Padua, Padua, Italy.
4
Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
5
Medical Genetics Unit, Dolo Hospital, Venice, Italy.
6
Endocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
PMID:
30655020
DOI:
10.1053/j.seminoncol.2018.12.005
No abstract available
Publication types
Letter
Comment
MeSH terms
Adrenocortical Carcinoma*
Antibodies, Monoclonal, Humanized
DNA Mismatch Repair
Disease Progression
Humans
Hydrocortisone*
Substances
Antibodies, Monoclonal, Humanized
pembrolizumab
Hydrocortisone